Novartis Stresses FDA Approvals In Zometa Trial
Novartis Pharmaceuticals Corp. on Wednesday tried to use a plaintiff's expert in New Jersey mass tort litigation over its bone drug Zometa to underscore U.S. Food and Drug Administration approvals for...To view the full article, register now.
Already a subscriber? Click here to view full article